Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02497950Completed

HeartMate 3 ELEVATE™ Registry

Role: collaborator

NCT01126944Not ApplicableWithdrawn

LVAD in Non Cardiac Transplant Candidates and Non Responders to Resynchronization

Role: collaborator

NCT01626404Completed

Screening for Advanced Heart Failure Treatment (SEE-HF)

Role: collaborator

NCT01477528Completed

Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

Role: collaborator

NCT00983190Not ApplicableCompleted

BeneMACS Study:HeartMate 2 (HM2)Left Ventricular Assist Device (LVAD) Survival in Non Transplant Patients is Equal/Better Than Results in Medical Literature

Role: collaborator

All 5 trials loaded